论文部分内容阅读
目的探讨氯沙坦联合血脂康胶囊治疗高血压病肾病的疗效及机制。方法选择高血压病肾病60例,随机分为治疗组和对照组各30例,对照组单用氯沙坦治疗,治疗组应用氯沙坦联合血脂康胶囊治疗,疗程6个月。观察治疗前后TC、TG、尿微量白蛋白(MALB)、24h尿蛋白、SCr、BUN值的变化。结果治疗前,二组TC、TG、MALB、24h尿蛋白、SCr、BUN值的比较差异无统计学意义(P>0.05),治疗6月后,与治疗前比较,除TC、TG外,二组患者的MALB、24h尿蛋白、SCr、BUN的值下降(P<0.01),治疗组的TC、TG、MALB、24h尿蛋白、SCr、BUN值较对照组低,差异有统计学意义(P<0.01)。结论采用氯沙坦和血脂康胶囊治疗高血压病肾病具有降血脂,减少尿蛋白,改善肾功能,延缓病情进展的作用。
Objective To investigate the efficacy and mechanism of losartan and Xuezhikang in the treatment of hypertensive nephropathy. Methods Sixty patients with hypertensive nephropathy were randomly divided into treatment group and control group with 30 cases each. The control group was treated with losartan alone. The treatment group was treated with losartan and Xuezhikang capsule for 6 months. The changes of TC, TG, urinary microalbumin (MALB), 24h urine protein, SCr, BUN before and after treatment were observed. Results Before treatment, urinary protein, SCr and BUN values of TC, TG, MALB and 24h in the two groups had no significant difference (P> 0.05). After 6 months of treatment, compared with before treatment, except TC and TG, The values of MALB, 24h urine protein, SCr and BUN in the treatment group decreased (P <0.01). The TC, TG, MALB, 24h urinary protein, SCr and BUN in the treatment group were lower than those in the control group <0.01). Conclusion Losartan and Xuezhikang Capsules for the treatment of hypertensive nephropathy have the effect of lowering blood fat, reducing urinary protein, improving renal function and slowing the progression of the disease.